Opioid Switching from Oxycodone to Morphine
Yes, switching from oxycodone to an equivalent dose of morphine is reasonable and appropriate when adequate pain relief is not achieved with oxycodone, but only after proper dose titration of the initial opioid has been attempted. 1
When to Consider Opioid Switching
Opioid switching should only be contemplated after:
- Adequate dose titration of oxycodone has been performed 1
- Attempts to address predictable side effects of the first-line opioid have been made 1
- The patient continues to experience uncontrolled pain despite dose escalation, or develops intolerable side effects 1
The ESMO guidelines explicitly state that a different opioid should be considered in the absence of adequate analgesia despite opioid dose escalation or in the presence of unacceptable opioid side effects. 1
Evidence Supporting Opioid Switching
While no randomized controlled trials exist to support opioid switching, the clinical evidence is compelling:
- The majority of patients (50-90%) experience improvement in pain control and/or reduction in side effects after switching opioids 1, 2
- A prospective randomized trial demonstrated a 95% response rate when both morphine and oxycodone were available for use as first- or second-line agents 3
- Individual response varies remarkably from opioid to opioid due to asymmetric tolerance, different efficacies, and pharmacokinetic profiles 1
The evidence quality is very low (no RCTs), but systematic reviews of uncontrolled studies consistently show benefit. 1, 4
Critical Conversion Considerations
Do not simply use a mathematical calculation for conversion ratios. The switch requires comprehensive assessment of: 1
- Underlying clinical situation
- Pain and adverse effect intensity
- Comorbidities and concomitant drugs
- Pharmacokinetic factors that could limit effectiveness
Conversion Ratio: Oxycodone to Morphine
The established conversion ratio from oral oxycodone to oral morphine is 1:1.5, meaning oxycodone is 1.5 times more potent than morphine. 5, 6
However, you must reduce the calculated morphine dose by 25-50% to account for incomplete cross-tolerance between different opioid agents. 5
For example:
- If a patient is taking 60 mg/day of oxycodone
- The equivalent morphine dose would be 90 mg/day (60 × 1.5)
- Reduce this by 25-50%, prescribing 45-67.5 mg/day of morphine initially 5
Special Populations Requiring Caution
Renal Impairment
Morphine carries higher risk in renal impairment compared to oxycodone. 1
- Morphine metabolites (M3G, M6G) accumulate in renal failure, increasing toxicity risk 1
- If morphine must be used in renal impairment, either increase the dosing interval or reduce the total dose 1
- Consider fentanyl, alfentanil, or methadone instead in patients with chronic kidney disease stages 4-5 (eGFR <30 mL/min) 1
Hepatic Dysfunction
Use additional caution and consider longer dosing intervals when prescribing to patients with hepatic dysfunction, as decreased clearance can lead to toxic accumulation. 1
Monitoring After the Switch
Evaluate the patient within 24-48 hours initially, then weekly during titration. 5 Monitor for:
- Pain intensity and functional status 5
- Opioid-related adverse effects including constipation, nausea, sedation, dizziness, and respiratory depression 5
- Signs of inadequate analgesia requiring further dose adjustment 1
Common Pitfalls to Avoid
- Never switch to extended-release/long-acting morphine formulations initially—use immediate-release morphine for titration 1
- Do not use full equianalgesic conversion ratios without dose reduction—incomplete cross-tolerance is universal 5
- Avoid abrupt discontinuation of oxycodone—taper gradually if overlapping during transition 7
- It is safer to underestimate the morphine dose than to overestimate and risk overdose 7
Alternative Considerations
If the switch from oxycodone to morphine fails to provide adequate relief:
- Consider switching to a third opioid (hydromorphone, fentanyl, or methadone) 1
- Methadone should only be used by experienced clinicians due to complex pharmacokinetics, variable conversion ratios (5:1 to 12:1 or higher), and risk of QT prolongation 1
- Evaluate for neuropathic pain components and consider adjuvant medications (gabapentin, pregabalin, tricyclic antidepressants) rather than continued opioid escalation alone 1, 8